A framework for assessing immunological correlates of protection in vaccine trials
- PMID: 17922394
- DOI: 10.1086/522428
A framework for assessing immunological correlates of protection in vaccine trials
Abstract
A central goal of vaccine research is to identify a vaccine-induced immune response that predicts protection from infection or disease. The term "correlate of protection" has been used to refer to at least 3 distinct concepts, which has resulted in confusion surrounding this topic. We propose precise definitions of these different concepts of immune correlates, using the nomenclature "correlate of risk," "level 1 surrogate of protection," and "level 2 surrogate of protection." We suggest a general framework for assessing these 3 levels of immune correlates in vaccine efficacy trials. To demonstrate the proposed principles, we analyze data from a 1943 influenza vaccine field trial, supporting Weiss strain A-specific antibody titers as a level 1 surrogate of protection. Other real and simulated examples are also discussed.
Comment in
-
Correlates, surrogates, and vaccines.J Infect Dis. 2007 Nov 1;196(9):1279-81. doi: 10.1086/522432. Epub 2007 Oct 2. J Infect Dis. 2007. PMID: 17922389 No abstract available.
Similar articles
-
Vaccines: correlates of vaccine-induced immunity.Clin Infect Dis. 2008 Aug 1;47(3):401-9. doi: 10.1086/589862. Clin Infect Dis. 2008. PMID: 18558875 Review.
-
Evaluation of the persistence of vaccine-induced protection with human vaccines.J Comp Pathol. 2010 Jan;142 Suppl 1:S96-101. doi: 10.1016/j.jcpa.2009.10.021. Epub 2009 Dec 4. J Comp Pathol. 2010. PMID: 19962714 Review.
-
Predictive models and correlates of protection for testing biodefence vaccines.Expert Rev Vaccines. 2010 May;9(5):527-37. doi: 10.1586/erv.10.22. Expert Rev Vaccines. 2010. PMID: 20450327 Review.
-
On the relationship between mean antibody level, seroprotection and clinical protection from influenza.Biologicals. 2009 Aug;37(4):216-21. doi: 10.1016/j.biologicals.2009.02.002. Epub 2009 Mar 5. Biologicals. 2009. PMID: 19268607
-
[Dengue fever: from disease to vaccination].Med Trop (Mars). 2009 Aug;69(4):333-4. Med Trop (Mars). 2009. PMID: 19725380 French.
Cited by
-
Development of functional and molecular correlates of vaccine-induced protection for a model intracellular pathogen, F. tularensis LVS.PLoS Pathog. 2012 Jan;8(1):e1002494. doi: 10.1371/journal.ppat.1002494. Epub 2012 Jan 19. PLoS Pathog. 2012. PMID: 22275868 Free PMC article.
-
HIV Vaccine Trials Network: activities and achievements of the first decade and beyond.Clin Investig (Lond). 2012 Mar;2(3):245-254. doi: 10.4155/cli.12.8. Clin Investig (Lond). 2012. PMID: 23243491 Free PMC article.
-
Nomenclature for immune correlates of protection after vaccination.Clin Infect Dis. 2012 Jun;54(11):1615-7. doi: 10.1093/cid/cis238. Epub 2012 Mar 20. Clin Infect Dis. 2012. PMID: 22437237 Free PMC article.
-
Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?J Clin Microbiol. 2022 Jun 15;60(6):e0048221. doi: 10.1128/jcm.00482-21. Epub 2022 Mar 7. J Clin Microbiol. 2022. PMID: 35249377 Free PMC article. Review.
-
Acute mucosal pathogenesis of feline immunodeficiency virus is independent of viral dose in vaginally infected cats.Retrovirology. 2010 Jan 19;7:2. doi: 10.1186/1742-4690-7-2. Retrovirology. 2010. PMID: 20085648 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical